Navigation Links
Peregrine Pharmaceuticals Reports Positive Data in Second Phase II Bavituximab Breast Cancer Trial
Date:4/27/2009

ced breast cancer and a Phase II combination therapy trial for the treatment of non-small cell lung cancer. A Phase I bavituximab monotherapy trial in advanced solid cancers is also continuing.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing three separate clinical programs in cancer and hepatitis C virus infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that the rate of objective tumor response for the expansion stage of this trial will not be consistent with the objective tumor response experienced in the first stage of the trial and the risk that the standard carboplatin and paclitaxel response rate will not be improved as a result of the combination therapy. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could c
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Peregrine Pharmaceuticals Awarded New U.S. Patent Further Strengthening Its Anti-Phospholipid Patent Portfolio
2. Nature Medicine study shows Peregrines bavituximab can cure lethal virus infections
3. Peregrine Pharmaceuticals to Present at the Cowen and Company 29th Annual Health Care Conference
4. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Lung Cancer Study
5. Nature Medicine study shows Peregrines bavituximab can cure lethal virus infections
6. Peregrine Pharmaceuticals Mourns Loss of Chairman Thomas A. Waltz
7. Peregrine Pharmaceuticals Enters Into a Loan Agreement for up to $10 Million
8. Peregrine Pharmaceuticals to Report Second Quarter FY 2009 Financial Results
9. Peregrine Pharmaceuticals to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
10. Peregrine Pharmaceuticals to Present at BIO Investor Forum 2008
11. Peregrine Pharmaceuticals Receives Additional Time to Regain Compliance With NASDAQs Minimum Bid Price Rule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... Fla. , July 11, 2014 /PRNewswire-iReach/ -- Maxim ... high-quality peptides that are used solely in scientific experiments, ... two successful years in business, Maxim Peptide, which was ... just launched a new and updated website that now ... blog section has been updated with fascinating articles about ...
(Date:7/11/2014)... , July 11, 2014 /CNW/ - Sunovion Pharmaceuticals Canada ... TM (eslicarbazepine acetate) for use as a once-daily ... patients with epilepsy who are not satisfactorily controlled with ... use in patients under 18 years of age. ... neurological disorders and according to Epilepsy Canada, it affects ...
(Date:7/10/2014)... UK (PRWEB) July 10, 2014 ... 21st Century Medicine Forum on ‘Commercialising Longevity Research’ ... and entrepreneurs to the London Bioscience Innovation Center ... Research Foundation and Aging Analytics Ltd. The meeting ... investment in translational research for age-related disease, as ...
(Date:7/10/2014)... July 10, 2014 OMICS Group’s 5th ... during 18-20 August, 2014 at Double Tree by Hilton ... recent developments in Analytical & Bioanalytical research methods only ... Speaking on this occasion, Dr. Srinubabu Gedela, MD of ... conference is a remarkable one in bringing a unique ...
Breaking Biology Technology:Maxim Peptide Celebrates Second Anniversary Online with an Updated Website and Special Deals Section 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4
... Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR ) today ... Genuity Annual Growth Conference on August 10, 2011 at ... Boston. (Logo:   http://photos.prnewswire.com/prnh/20090413/LA97352LOGO ) ... accessible in the Investors section of the Company,s website ...
... of bacteria in hospitals is increasing. Bacteria acquire resistance ... incorporating new genes, either from the surrounding environment or ... Portuguese CBA research (University of Lisbon) and the Instituto ... mechanisms of resistance are playing out in the bacterium ...
... tiny hair-like structures that perform feats such as clearing ... location of organs during development, move in mysterious ways. ... similar in appearance to "the wave" created in large ... a pattern of movement around the entire stadium. ...
Cached Biology Technology:Bacterial resistance to antibiotics: The more they resist, the more they divide 2Brandeis lab's artificial cilia spur new thinking in nanotechnology 2
(Date:7/11/2014)... of kidney injury related to the use of hydroxyethyl ... HES molecules, according to a report in Anesthesia ... Research Society (IARS). , The "total mass of HES ... human renal proximal tubule cells (PTCs), concludes the laboratory ... Hospital Wrzburg, Austria. Other factorssuch as differences in ...
(Date:7/11/2014)... normal circumstances, astrocytes participate in normal physiological ... exhibit therapeutic and repairing effects on brain ... found that nerve cells differentiated from adipose-derived ... viability, which produces influences on subsequent studies ... Hospital, Hebei United University, China demonstrated that ...
(Date:7/11/2014)... to study the proteins that let nerve cells send ... stumbled upon a biological tactic that may offer a ... a safe and environmentally responsible way. , Their ... one species and harmless for a closely related onesuggests ... without harming beneficial species like bees. A summary of ...
Breaking Biology News(10 mins):In lab studies, hydroxyethyl starch has direct harmful effects on kidney cells 2Potent spider toxin 'electrocutes' German, not American, cockroaches 2Potent spider toxin 'electrocutes' German, not American, cockroaches 3
... in the world to have survived exposure to the vacuum ... Ingemar Jnsson, a researcher at Kristianstad University in Sweden. ... Jnsson had some 3,000 microscopic water bears sent up on ... project, which was supported by the European Space Agency, was ...
... September, in the context of France,s presidency of the ... at the Grand Palais. The GMES (Global Monitoring ... to provide services relating to the environment, climate change, ... on data - mainly Earth observation data - from ...
... clear skies and smooth sailing for oceanic vessels has ... to air pollution and greenhouse gas emissions that impact ... James Winebrake and James Corbett examines "Emission Tradeoffs among ... Oil, Marine Gas Oil, and Marine Diesel Oil," in ...
Cached Biology News:Major European program for the environment under the spotlight in Lille, France 2Fuel emissions from marine vessels remain a global concern 2
... The mini incubation trays ... used to screen antigens that ... membrane. Each tray has eight ... channels that accommodate strips cut ...
... analysis and experiment control software. Records ... on-line and off-line analysis. powerful stimulus ... language allowing the user to customize ... Applications range from basic data logging ...
... • Small design specifically for western ... ,Trays are specifically designed for staining western ... x 25 mm) of the disposable tray ... a significant cost savings to the user. ...
... a direct antibiotic-based selection ... Recombinant selection depends solely ... the need for costly ... and inexpensive process provides ...
Biology Products: